Endo Pharma Announces Commercial Availability Of NATESTO, Testosterone Nasal Gel

(RTTNews) - Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (ENDP, ENL.TO), announced the commercial availability of NATESTO, the first and only nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism.

NATESTO was approved by the U.S. FDA in May 2014 for replacement therapy in adult men with conditions associated with deficiency or absence of endogenous testosterone, including primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired). In 2014, Endo acquired the rights to NATESTO in the U.S. and Mexico from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation (TRL.TO).